Finance News

MabVax Therapeutics Holdings, Inc. Announces $500,000 Registered Direct Offering

3.8 from 4 votes
Wednesday, October 11, 2017

SAN DIEGO - MabVax Therapeutics Holdings, Inc. (Nasdaq: MBVX), a clinical-stage biotechnology company focused on the development of antibody-based products to address unmet medical needs in the treatment of cancer, announced that it has agreed to sell 769,231 shares of its common stock for gross proceeds of approximately $500,000. Each share of common stock is being sold at a price of $0.65 per share.

The shares were offered and are being sold to certain accredited investors in a registered direct offering. The net proceeds from the offering, after deducting estimated offering expenses, will be approximately $470,000. The offering is expected to close on or about October 12, 2017.

MabVax intends to use the net proceeds of the offering primarily to fund continuing clinical development of two programs:

The Company's HuMab 5B1 antibody designated as MVT-5873 is being studied in combination with gemcitabine and nab-paclitaxal in first line therapy for the treatment of patients newly diagnosed with pancreatic cancer. The Company has treated two cohorts of patients for a total of six patients to date in this study, and these funds will enable the Company to enroll an additional cohort of patients with the objective of confirming early observations.
The Company's radioimmunotherapy product designated as MVT-1075 is being studied for the treatment of locally advanced or metastatic pancreatic cancer patients. MabVax initiated the Phase 1 study of MVT-1075 in June 2017 and intends to treat additional patients to continue to assess the safety and potential efficacy of this treatment.

The securities were offered by means of a shelf registration statement on Form S-3 (File # 333-219291) which was declared effective on July 27, 2017, by the Securities and Exchange Commission, or SEC. A prospectus supplement and accompanying base prospectus relating to the offering of the securities will be filed with the SEC and will be available on the SEC web site at Copies of the final prospectus supplement and accompanying prospectus relating to this offering may be obtained, when available, by calling MabVax at 858-259-9405.

About MabVax

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company with a fully human antibody discovery platform focused on the rapid translation into clinical development of products to address unmet medical needs in the treatment of cancer. Our antibody MVT-5873, is a fully human IgG1 monoclonal antibody (mAb) that targets sialyl Lewis A (sLea), an epitope on CA19-9, and is currently in Phase 1 clinical trials as a therapeutic agent for patients with pancreatic cancer and other CA19-9 positive tumors. CA19-9 is expressed in over 90% of pancreatic cancers and in other diseases including small cell lung and GI cancers. CA19-9 plays an important role in tumor adhesion and metastasis, and is a marker of an aggressive cancer phenotype. CA19-9 serum levels are considered a valuable adjunct in the diagnosis, prognosis and treatment monitoring of pancreatic cancer. With our collaborators including Memorial Sloan Kettering Cancer Center, Sarah Cannon Research Institute, Honor Health and Imaging Endpoints, we have treated 50 patients with either our therapeutic antibody designated as MVT-5873 or our PET imaging diagnostic product designated as MVT-2163 in Phase 1 clinical studies, and demonstrated early safety and specificity for the target. Patient dosing has commenced for our lead development program in Phase 1 clinical study of the Company's radioimmunotherapy product MVT-1075. For additional information, please visit the Company's website,

Source: MabVax Therapeutics Holdings, Inc.
3.8 from 4 votes
Free Newsletter